On November 5, 2020, Pourhassan told shareholders, "And in regards to any other, any other data that you’re talking about, we need receptor occupancy for our HIV. If we are able to tell the world that we just came up with a receptor occupancy that actually tells us who will respond positively to Mono therapy. If we find that, you don’t even need tropism test, you will be able to just tell the FDA here is the receptor occupancy, this patient can be a responder, and this won’t. And if you get that, it’s a huge, huge announcement".